With this submission of a competitive renewal application of our training grant titled ?Graduate Training in Cancer Research?, we are seeking five years of support for a Training Program that has been continually funded since 1975. Since that time, more than 500 physicians and physician-scientists who were part of fellowship training programs in medical oncology and, initially, pediatric oncology at the Dana-Farber Cancer Institute received, through this funding mechanism, the essential support and protected time that they required to launch an academic career. Of the 114 trainees who have been supported by this training program during the past 15 years, 18 continue as fellows. Of the remaining 96, 95% presently hold full-time academic positions at medical centers throughout the United States and 92% have received independent funding. With the present application, we seek to continue this tradition of training leaders in academic oncology. The future of cancer research will continue to depend on the continued training of highly-talented and creative physician-scientists who possess an understanding of the clinical aspects of neoplastic disease, are able to apply these concepts to appropriate laboratory issues or health services within the many areas of tumor biology and population sciences, and emerge as academic leaders with sufficient skills to direct research programs, patient care, and educational efforts. The development of such individuals can only be accomplished within an environment where physicians and scientists work in physically adjacent areas, exchanging ideas and collaborating on a wide array of endeavors. The program will build on a foundation of excellence in Medical Oncology established during clinical training in the Dana-Farber/Partners CancerCare Hematology/Oncology Fellowship Program. All of these candidates have already received an MD or MD/PhD degree, completed 2 or 3 years of Internal Medicine residency, and at least one year of clinical training in Medical Oncology. Some trainees may have also completed an additional 6 months of training in Hematology. The training grant program will select the most highly qualified candidates from this pool who wish to pursue laboratory research or clinical investigation at the Dana-Farber Cancer Institute or nearby surrounding institutions. The program will provide outstanding mentored laboratory and clinical investigation research experiences from senior and experienced junior faculty and support for the recruitment and mentorship of under-represented minority fellows. It is expected that at the conclusion of their training, those individuals supported by this training program will have the ability to design, initiate, and complete individual clinical or laboratory research projects, will be able to function independently or with minimal supervision, and will be positioned to soon establish themselves as independent research investigators.

Public Health Relevance

The overall objective of this Training Program is to prepare the next generation of leaders in Medical Oncology in laboratory and clinical translational sciences. The program will provide outstanding mentored laboratory and clinical investigation research experiences from senior and experienced junior faculty and support for the recruitment and mentorship of under-represented minority fellows. It is expected that at the conclusion of their training, those individuals supported by this training program will have the ability to design, initiate, and complete individual clinical or laboratory research projects, will be able to function independently or with minimal supervision, and will be positioned to soon establish themselves as independent research investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009172-45
Application #
9899740
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Schmidt, Michael K
Project Start
1980-07-01
Project End
2022-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lo, Justin H; Hao, Liangliang; Muzumdar, Mandar D et al. (2018) iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther 17:2377-2388
Gannon, Hugh S; Zou, Tao; Kiessling, Michael K et al. (2018) Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun 9:5450
Boija, Ann; Klein, Isaac A; Sabari, Benjamin R et al. (2018) Transcription Factors Activate Genes through the Phase-Separation Capacity of Their Activation Domains. Cell 175:1842-1855.e16
Lampson, Benjamin L; Brown, Jennifer R (2018) Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol 11:185-194
Aref, Amir R; Campisi, Marco; Ivanova, Elena et al. (2018) 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab Chip 18:3129-3143
Kapp, Friedrich G; Perlin, Julie R; Hagedorn, Elliott J et al. (2018) Protection from UV light is an evolutionarily conserved feature of the haematopoietic niche. Nature 558:445-448
Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215
Lampson, Benjamin L; Brown, Jennifer R (2017) PI3K?-selective and PI3K?/?-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs 26:1267-1279
Lampson, Benjamin L; Davids, Matthew S (2017) The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep 12:11-19
Meehan, Terrence F; Conte, Nathalie; Goldstein, Theodore et al. (2017) PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Res 77:e62-e66

Showing the most recent 10 out of 241 publications